Bilcare Limited
301 Kamal Kunj
8 Shivaji Housing Society
Pune 411 016 India

Tel +91 20 6600 7559

direct.bil@bilcare.com
www.bilcare-group.com

Bilcare Research

Date: 13 August 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 526853

Sub: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI LODR Regulations, we hereby inform you that the Board of Directors, at its meeting held on 13 August 2026, has approved the following:

A. Unaudited Financial Results for the quarter ended June 30, 2026

Pursuant to Regulation 33 of the SEBI LODR Regulations, we are enclosing herewith the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, together with the Limited Review Report issued by the Statutory Auditors of the Company.

The aforesaid financial results were duly considered and approved by the Board of Directors of the Company at its meeting held on August 13, 2026.

B. Changes in Directors

- Appointment of Mr. Mohan Bhandari as an Executive Director of the Company, with effect from August 13, 2026, subject to the approval of the Members in the ensuing General Meeting of the Company. The requisite disclosure as prescribed under the SEBI LODR Regulations is enclosed herewith as Annexure A.
- Reappointment of Ms. Kavita Bhansali as Executive Director for a further term of five years, subject to the approval of the Members in the ensuing General Meeting of the Company. The requisite disclosure as prescribed under the SEBI LODR Regulations is enclosed herewith as Annexure B.

C. Changes in Key Managerial Personnel – Resignation and Appointment of Company Secretary

a. Mr. Sagar R. Baheti, Company Secretary, Compliance Officer and Key Managerial Personnel of the Company, has tendered his resignation from the position of Company Secretary and Compliance Officer on August 13, 2026.

b. The Board of Directors has approved the appointment of Mr. Mayur Dave, Company Secretary, Compliance Officer and Key Managerial Personnel of the Company.

The requisite disclosure as prescribed under the SEBI LODR Regulations is enclosed herewith as Annexure C.

D. Voluntary winding up of Bilcare INC

The proposal of voluntary winding up of Bilcare INC, a wholly owned subsidiary of the Company in United States of America, as per the applicable laws of United States of America. The said subsidiary is not a material subsidiary of the Company.

Bilcare Limited

Bilcare Limited
301 Kamal Kunj
8 Shivaji Housing Society
Pune 411 016 India

Tel +91 20 6600 7559

direct.bil@bilcare.com
www.bilcare-group.com

Bilcare Research

The requisite disclosure as prescribed under the SEBI LODR Regulations is enclosed herewith as Annexure D.

The Board meeting commenced at 04:30 P.M. and concluded at 08:30 P.M. (IST). You are requested to take the same on record and confirm receipt of the same.

Thanking you,

Yours faithfully,

For Bilcare Limited

Sagar R. Baheti
Bilcare Limited
Date: 2026.08.13 22:47:00 +05'30'
Adobe Acrobat version: 2026.001.21789

Bilcare Limited

Sagar R. Baheti
Company Secretary

Encl: as above

Bilcare Limited
Registered Office: 1028, Shiroli, Pune 410 505. Tel : +91 2135 647300 Fax : +91 2135 224068
Email : cs@bilcare.com Website : www.bilcare-group.com
CIN : L28939PN1987PLC043953

A. Quarterly Integrated Filing (Financials)

Standalone Unaudited Financial Results for the quarter ended 30 June 2026

(₹ in Crores)

Sr.No.	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1.	**Income**				
	Revenue from operations	1.94	1.20	2.07	6.85
	Other Income	4.36	3.82	6.72	19.53
	Total income	6.30	5.02	8.79	26.38
2.	**Expenses**				
	a. Cost of materials consumed	0.53	0.12	0.67	1.77
	b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	c. Employee benefits expense	1.20	0.78	1.29	4.87
	d. Finance costs	0.12	0.14	0.14	0.60
	e. Depreciation and amortisation expense	0.60	0.61	0.68	2.72
	f. Other expenses	1.20	8.28	1.52	12.70
	Total expenses	3.65	9.93	4.30	22.66
3.	Profit / (Loss) before tax and exceptional items (1-2)	2.65	(4.91)	4.49	3.72
4.	Exceptional items	(1.74)	(2.08)	-	(2.16)
5.	Profit / (Loss) before tax (3 + 4)	0.91	(6.99)	4.49	1.56
6.	Tax expense	(0.13)	(0.64)	0.90	0.57
	(i) Current tax	-	-	-	-
	(ii) Adjustment of tax relating to earlier years	-	-	-	-
	(iii) Deferred tax	(0.13)	(0.64)	0.90	0.57
7.	Net Profit / (Loss) for the period (5-6)	1.04	(6.35)	3.59	0.99
8.	Other comprehensive income				
	A (i) Items that will not be reclassified to profit or loss	(0.03)	0.23	-	0.37
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.01	(0.13)	-	(0.13)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Other comprehensive income, net of taxes	(0.02)	0.10	-	0.24
9.	**Total comprehensive income (7+8)**	1.02	(6.25)	3.59	1.23
10.	Paid-up Equity Share Capital (face value Rs.10/- each)	23.55	23.55	23.55	23.55
11.	Reserves i.e. Other equity	-		-	397.34
12.	Earnings Per Share (EPS) (Face value Rs. 10/- per share)				
	a Basic EPS	0.44	(2.70)	1.52	0.42
	b Diluted EPS	0.44	(2.70)	1.52	0.42

PATKI & SOMAN F.R. No. 107830W PUNE Chartered Accountants

Bilcare Limited

Bilcare Limited
Registered Office: 1028, Shiroli, Pune 410 505. Tel : +91 2135 647300 Fax : +91 2135 224068
Email : cs@bilcare.com Website : www.bilcare-group.com
CIN : L28939PN1987PLC043953

Standalone Notes:

1 The Company has only one reportable segment namely "Pharma Packaging Research Solutions".

2 The above results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 The accounts are prepared on a going-concern basis given the positive prospects going forward, including Management's strategic plan for the foreseeable future, cash flow projection, and future business prospects for the GCS Business.

4 In respect of the public fixed deposit liability taken over by the Caprihans India Limited (CIL) as per the Business Transfer Agreement (BTA), the statutory compliances is the responsibility of the Company. Further in line with the BTA, the additional interest for cumulative fixed deposits has been expensed as interest cost. The Company had received an order from Hon'ble National Company Law Tribunal Mumbai, dated 5th June 2026, directing Company to transfer the outstanding amount to the Investor Education Protection Fund (IEPF) on or before 15th July 2026. In accordance with the aforesaid order, the Company has complied with the directions contained therein, including the transfer of Rs. 2.93 crores (inclusive of Rs. 2.34 crores which is pertaining to Caprihans India Limited) to the IEPF maintained by the Government of India on 10th July 2026.

5 The land parcels against advance which were capitalized in FY 2023-24, is continued to be shown as "Asset Held for Sale" as at June 30, 2026 having a book value of Rs 64.07 crores.

6 The penal interest as per the agreement terms w.r.t. CSIR loan of Rs. 18.55 crores is considered under Contingent Liability. The matter is currently sub-judice.

7 As on 31st March 2026, the company had option for conversion of 20,20,000 warrants, for which Rs.10.10 Crores had been paid as warrant subscription amount. During the quarter ended, June 2026 the company paid INR 25.58 Crores being 75% of the 17,05,000 outstanding warrants. Conversion option attached to 3,15,000 share warrants were not exercised. Hence the aforesaid warrants lapsed and the amount was forfeited. Impact of same has been considered under exceptional items.

8 The Company is under investigation by the SFIO pursuant to the MCA's order dated 3 June 2020. The Hon'ble Bombay High Court disposed of the existing writ petition while granting liberty to file a fresh petition. The financial impact, if any, is presently not ascertainable.

9 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 13, 2026.

10 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the end of third quarter of the respective financial year, which was subject to limited review.

11 Previous periods' figures have been re-grouped / re-classified wherever necessary.

PATKI & SOMAN Chartered Accountants F.R. No. 107830W PUNE

Bilcare Limited

For Bilcare Limited

Shreyans Bhandari

Shreyans M. Bhandari
Managing Director

Pune: August 13, 2026

PATKI & SOMAN
Chartered Accountants

HEAD OFFICE : 101/102, Parmesh Plaza, 1213, Sadashiv Peth, Near Hatti Ganpati, Pune - 411 030.
Telephone : 24456748, 24446748 Web : www.patkiandsoman.com E-mail : patkiandsoman@gmail.com

Ref. : Date :

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Bilcare Limited

1. We have reviewed the accompanying statement of Standalone Unaudited Financial results of Bilcare Limited (the "Company") for the quarter ended June 30, 2026, together with notes thereon (the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. The Company's Board of Directors is responsible for the preparation and fair presentation of the Statement in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013("the Act") as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in para 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Act, read with the relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

PATKI & SOMAN F.R. No. 107830W PUNE Chartered Accountants

5. **We draw your attention to:**

a) Note no. 3 of the Statement, the Company has incurred operating losses in the past years indicating the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern. However, based on discussions with management, the Company's ability to continue as a going concern is dependent upon factors such as the execution of its strategic plans, projected cash flows, and future business prospects for the GCS business. In view of the positive outlook for the GCS business, as represented by the management, the statements have been prepared on a going concern basis.

b) Note no. 4 to the Statement, the public fixed deposit liability has been taken over by Caprihans India Limited in terms of the Business Transfer Agreement ("BTA"). Under this agreement, the Company is responsible for all related statutory compliances. In line with the BTA, the additional interest on cumulative fixed deposits has been recognised as interest cost in the Statement.
In respect of these PFDs, Company had received an order from the National Company Law Tribunal, Mumbai, dated 05th June 2026, directing Company to transfer the outstanding amount to the Investor Education and Protection Fund (IEPF) on or before 15th July 2026. As per the information and details provided to us, the said amount of Rs. 2.93 crores inclusive of 2.34 crores which is Caprihans India Limited's liability, has been transferred to the IEPF.

c) Note no. 5 in the Statement which states that the Company had planned to sell certain capital assets in FY 2024-25. Accordingly, the assets scheduled for sale in FY 2024-25 continue to be classified as 'assets held for sale' as of 30th June 2026.

d) Note 6 in the Statement, penal interest of Rs.18.55 crores on the CSIR loan has been disclosed as a contingent liability and the matter is sub judice.

e) Note 7 in the statement, as at 31st March 2026 the company had option for conversion of 20,20,000 warrants for which Rs.10.10 crores had been paid as warrant subscription amount. During the quarter ended the company paid Rs.25.58 crores being 75% of the 17,05,000 outstanding warrants. Conversion option attached to 3,15,000 share warrants were not exercised. Hence, the aforesaid warrants lapsed and the amount was forfeited.

f) Note no. 8 in the statement with respect to ongoing investigations by the SFIO. The Hon'ble Bombay High Court disposed of the existing writ petition while granting liberty to file a fresh petition.

Our conclusion is not modified in respect of matters stated in para 5 (a) to (f) above.

For PATKI AND SOMAN
Chartered Accountants
Firm Registration No. 107830W

PATKI & SOMAN F. R. No. 107830W PUNE Chartered Accountants

Rahul D. Kulkarni
(Partner)
Membership No. 158616
Place: Pune
Date: 13th August 2026
UDIN: 26158616ZMUEZX3651

Bilcare Limited
Registered Office: 1028, Shiroli, Pune 410 505. Tel : +91 2135 647300 Fax : +91 2135 224068
Email : cs@bilcare.com Website : www.bilcare-group.com
CIN : L28939PN1987PLC043953
Consolidated Unaudited Financial Results for the quarter ended 30 June 2026

(₹ in Crores)

Sr.No.	Particulars	Quarter ended			Year ended
		30 June 2026 (Unaudited)	31 March 2026 (Audited)	30 June 2025 (Unaudited)	31 March 2026 (Audited)
1.	**Income**				
	Revenue from operations	225.86	187.66	186.36	733.54
	Other Income	1.75	14.46	6.08	30.00
	Total income	227.61	202.12	192.44	763.54
2.	**Expenses**				
	a. Cost of materials consumed	142.68	124.21	128.32	494.17
	b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3.48)	(7.57)	(2.61)	(4.27)
	c. Employee benefits expense	19.77	19.32	20.02	79.96
	d. Finance costs	18.08	17.69	18.55	72.34
	e. Depreciation and amortisation expense	4.11	4.78	4.64	19.75
	f. Other expenses	29.87	34.77	29.56	119.25
	Total expenses	211.03	193.20	198.48	781.20
3.	Profit / (Loss) before tax and exceptional items (1-2)	16.58	8.92	(6.04)	(17.66)
4.	Exceptional items	(1.74)	(2.00)	-	(3.80)
5.	Profit / (Loss) before tax (3 + 4)	14.84	6.92	(6.04)	(21.46)
6.	Tax expense	(0.13)	(0.93)	(3.20)	(4.17)
	(i) Current tax	-	(0.05)	-	(0.05)
	(ii) Adjustment of tax relating to earlier years	-	-	-	-
	(iii) Deferred tax	(0.13)	(0.88)	(3.20)	(4.12)
7.	**Net Profit / (Loss) for the period (5-6)**	14.97	7.85	(2.84)	(17.29)
8.	Other comprehensive income				
	A (i) Items that will not be reclassified to profit or loss	(1.09)	(0.61)	(0.17)	2.64
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.01	(0.13)	0.04	(0.01)
	B (i) Items that will be reclassified to profit or loss	(0.03)	0.29	0.31	0.89
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Other comprehensive income, net of taxes	(1.11)	(0.45)	0.18	3.52
9.	**Total comprehensive income (7+8)**	13.86	7.40	(2.66)	(13.77)
10.	Profit attributable to:				
	(i) Owners of equity	12.70	13.37	3.19	1.72
	(ii) Non-controlling interests	2.27	(5.52)	(6.03)	(19.01)
11	Other comprehensive income attributable to:				
	(i) Owners of equity	(0.72)	(10.31)	(12.77)	2.53
	(ii) Non-controlling interests	(0.39)	9.86	6.03	0.99
12.	Total comprehensive income attributable to:				
	(i) Owners of equity	11.98	3.06	(9.58)	4.25
	(ii) Non-controlling interests	1.88	4.34	-	(18.02)
13	Paid-up Equity Share Capital (face value Rs.10/- each)	23.55	23.55	23.55	23.55
14	Reserves i.e. Other equity	-	-	-	173.18
15	Earnings Per Share (EPS) (Face value Rs. 10/- per share)				
	a. Basic EPS	5.39	5.68	1.34	0.73
	b. Diluted EPS	5.39	5.68	1.34	0.73

PATKI & SOMAN F. R. No. 107830W PUNE Chartered Accountants

Bilcare Limited

Consolidated Notes:

1 All Standalone notes also pertain for the Consolidated financial results.

2 With reference to Caprihans India Limited (CIL) -

(i) The Company is primarily engaged in Pharma Packaging Solutions, and its products are covered under a single reportable segment.

(ii) Bilcare Research GmbH a wholly owned subsidiary of the Company has been consolidated in the Consolidated financial results of the Group for the period ended June 30, 2026.

(iii) During the financial year ending March 31, 2025, the Company on 3rd and 5th December 2024 had approved for issue and allotment of 48,00,000 Convertible Warrants (hereinafter referred to as "Warrants") at an issue price of Rs. 200/- each on a preferential basis for an aggregate amount of Rs. 96.00 Crores, against receipt of Rs.24.00 crores as Warrant Subscription; amount being equivalent to 25% of the total consideration, with each Warrant convertible into one equity share of the Company within a period of 18 months from the date of allotment of Warrants at a conversion price of Rs.200/ per Warrant (including Rs. 190 per share towards share premium), to the Allottees ("Allottees") of share warrant. As on 31st March 2026, the company had 20,20,000 warrants outstanding, for which Rs.10.10 Crores had been received as warrant subscription amount. During the quarter ended, June 2026 the company received INR 25.58 Crores being 75% of the 17,05,000 outstanding warrants.

Conversion option attached to 3,15,000 share warrants were not exercised within 18 months from the date of allotment i.e. 05th December 2024; hence, the Board of Directors of the Company in the meeting dated 05th June 2026 has approved the forfeiture of the money received of Rs.1.58 Crores from the share warrant holders which has been transferred to capital reserve.

(iv) During the year, the Company has redeemed 2,55,75,500 0.1% Redeemable Preference Shares (RPS) of Rs. 10/- each issued to Bilcare Limited and the same stands reduced to the equivalent amount

(v) In respect of the arrangement with Bilcare Limited (Bilcare) for the repayment of principal and interest on the public fixed deposit liability taken over by the Company as per the Business Transfer Agreement, the outstanding as at June 30, 2026 is Rs. 2.34 crores (including interest) which was fully earmarked and maintained with PFD Escrow account. In respect of these PFDs, Bilcare had received an order from the National Company Law Tribunal, Mumbai, dated 05th June 2026, directing Bilcare to transfer the outstanding amount to the Investor Education and Protection Fund on or before 15th July 2026 and to publish an advertisement/ notice of the same in vernacular and English newspapers. Accordingly, the outstanding amount has been transferred to the Investor Education and Protection Fund and the statutory compliances related to Public fixed deposit is the responsibility of Bilcare Limited.

3 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 13, 2026.

4 Previous periods' figures have been re-grouped / re-classified wherever necessary.

PATKI & SOMAN Chartered Accountants F.R. No. 107830W PUNE

Bilcare Limited

For Bilcare Limited

Shreyans Bhandari

Shreyans M. Bhandari
Managing Director

Pune: August 13, 2026

PATKI & SOMAN
Chartered Accountants

HEAD OFFICE : 101/102, Parmesh Plaza, 1213, Sadashiv Peth, Near Hatti Ganpati, Pune - 411 030.
Telephone : 24456748, 24446748 Web : www.patkiandsoman.com E-mail : patkiandsoman@gmail.com

Ref. : Date :

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Bilcare Limited pursuant to the Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, as amended

To,
The Board of Directors
Bilcare Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results ("the Statement") of Bilcare Limited ("the Holding Company") and its subsidiaries ('the Holding company and it's subsidiaries together referred to as 'the Group') for the quarter ended June 30, 2026, being submitted by the Holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. The Holding Company's Management is responsible for the preparation and fair presentation of the Statement in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013("the Act") as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Holding Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

PATKI & SOMAN
F. R. No. 107830W
PUNE
Chartered Accountants

4. The Statement includes the results of the entities mentioned in **"Annexure A"** to this report.

5. Based on our review conducted stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Act, read with the relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. **We draw your attention to**

a) Note no. 3 of the Standalone Financial Statement, the Holding Company has incurred operating losses in the past years indicating the existence of a material uncertainty that may cast significant doubt on the Holding Company's ability to continue as a going concern. However, based on discussions with management, the Holding Company's ability to continue as a going concern is dependent upon factors such as the execution of its strategic plans, projected cash flows, and future business prospects for the GCS business. In view of the positive outlook for the GCS business, as represented by the management, the statements have been prepared on a going concern basis.

b) Note no. 4 in the Standalone Financial Statementss, the public fixed deposit liability has been taken over by Caprihans India Limited (the Subsidiary Company) in terms of the Business Transfer Agreement ("BTA"). Under this agreement, the Holding Company is responsible for all related statutory compliances. In line with the BTA, the additional interest on cumulative fixed deposits has been recognised as interest cost in the Statement.
In respect of these PFDs, the Holding Company had received an order from the National Company Law Tribunal, Mumbai, dated 05th June 2026, directing the Holding Company to transfer the outstanding amount to the Investor Education and Protection Fund (IEPF) on or before 15th July 2026. As per the information and details provided to us, the said amount of Rs. 2.93 crores inclusive of 2.34 crores which is the Subsidiary Company's liability, has been transferred to the IEPF.

c) Note No. 5 in the Standalone Financial Statements which states that the Holding Company had planned to sell certain capital assets in FY 2024-25. Accordingly, the assets scheduled for sale in FY 2024-25 continue to be classified as 'assets held for sale' as of 30th June 2026.

d) Note no. 8 in the Standalone Financial Statements with respect to ongoing investigations by the SFIO. The Hon'ble Bombay High Court disposed of the existing writ petition while granting liberty to file a fresh petition.

e) Separate Interim financial information of one domestic subsidiary included in the Statements is prepared and certified by such Subsidiary Company's management and is not subjected to review by their statutory auditor whose financial information reflects total revenue as Rs.0.00 crores and total comprehensive Income of Rs. (0.09) Crores for the quarter ended 30th June 2026 respectively. Our conclusion on the accompanying Statement in so far as it relates to the amounts and disclosures included in respect of this domestic subsidiary is

PATKI & SOMAN
F. R. No. 107830W
PUNE
Chartered Accountants

based solely on the management prepared and certified financial information. As informed by the Holding Company's management this domestic subsidiary as mentioned above is not material to the group.

f) We did not review the interim financial information of three foreign subsidiaries and one indirect subsidiary, included in the Consolidated Financial Results, whose interim financial information reflects total revenue of Rs. 4.35 Crores and total Comprehensive income of Rs. (0.98) Crores for quarter ended 30th June 2026. This unaudited financial information has been furnished to us by the Holding company's management and management of Caprihans India Limited respectively. Our conclusion on the statement, in so far as it is related to amounts and disclosures in respect of this subsidiary, is based solely on such unaudited interim financial information.

Our conclusion is not modified in respect matters stated in 6 (a) to (f) above.

For PATKI AND SOMAN
Chartered Accountants
Firm Registration No. 107830W

PATKI & SOMAN
F. R. No. 107830W PUNE
Chartered Accountants

Rahul D. Kulkarni
(Partner)
Membership No. 158616
Place: Pune
Date: 13th August 2026
UDIN: 26158616FICOOE6104

"Annexure A"

Annexure A to the Independent auditor's Limited Review Report on Consolidated Unaudited financial results of Bilcare Limited for the quarter ended 30th June 2026

Direct Subsidiaries:

1. Bilcare Pharma Solutions Limited
2. Caprihans India Limited
3. Bilcare GCS Ireland
4. Bilcare GCS Inc. US
5. Bilcare Inc. US

Indirect Subsidiaries:

1. Bilcare Research GmbH (Subsidiary of Caprihans India Limited)

PATKI & SOMAN
F. R. No. 107830W
PUNE
Chartered Accountants

Bilcare Limited
301 Kamal Kunj
8 Shivaji Housing Society
Pune 411 016 India

Tel +91 20 6600 7559

direct.bil@bilcare.com
www.bilcare-group.com

Bilcare Research

Annexure A

Details under Regulation 30 of the SEBI Listing Regulations, read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No.	Particulars	Details
1.	Name of Director / KMP	Mr. Mohan Bhandari (DIN: 00052777)
2.	Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Appointment as Executive Director of the Company. Mr. Mohan Bhandari, Founder, Promoter and CEO of the Company and has now been appointed as Executive Director. The appointment is subject to the approval of the Members in the ensuing General Meeting.
3.	Date of appointment / ~~re-appointment / cessation~~ (as applicable) & term of appointment / re-appointment	Effective Date: 13 August 2026. Term of Appointment: Appointed for a period of 5 (five) consecutive years with effect from 13 August 2026, subject to the approval of the Members of the Company.
4.	Brief profile (in case of appointment)	Mr. Mohan Bhandari is the Founder and Promoter of Bilcare Limited and the architect of Bilcare Research. A first-generation technocrat-entrepreneur with over 39 years of experience, he has guided the Company from its inception into an internationally recognized and respected enterprise, driven by the philosophy of "Transforming Innovations – Touching Lives." Mr. Bhandari brings deep and diverse expertise across specialty materials, products, processes, services and technology, with a strong focus on translating scientific and technological capabilities into end-use applications for the pharmaceutical and healthcare sectors. His areas of expertise encompass materials science and specialty packaging engineering, anti-counterfeiting and brand-protection technologies, and global clinical supply-chain solutions. In recognition of his significant and sustained contribution to the pharmaceutical industry, he was conferred the Lifetime Achievement Award at the 59th Indian Pharmaceutical Conference in 2007. As Executive Director, Mr. Bhandari will provide founder-led strategic direction, technical leadership and institutional continuity. His role will include strategic oversight of the Company's robust and differentiated product portfolio, leveraging his extensive scientific and entrepreneurial experience, while continuing to nurture key global stakeholder relationships and support the Company's long-term growth agenda. Mr. Bhandari will provide strategic leadership and Board-level guidance, leveraging his extensive industry experience and deep understanding of the Company. His continued involvement will strengthen

Bilcare Limited

Bilcare Limited
301 Kamal Kunj
8 Shivaji Housing Society
Pune 411 016 India

Tel +91 20 6600 7559

direct.bil@bilcare.com
www.bilcare-group.com

Bilcare Research

		Company's materials science-led growth strategy, particularly across high-growth segments of the pharmaceutical and healthcare industries strategic decision-making, execution of key initiatives, innovation and long-term growth.
5.	Disclosure of relationships between directors (in case of appointment of a Director)	Mr. Mohan Bhandari is a Promoter of the Company and is related to key board members as under: • Father of Mr. Shreyans Bhandari (Chairman & Managing Director) • Father of Ms. Kavita Bhansali (Executive Director)
6.	Information required pursuant to BSE Circular ref no. LIST/COMP/14/2018-19 and NSE Circular ref no. NSE/CPL/2018/24 dated June 20, 2018	Mr. Mohan Bhandari is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.
7.	Shareholding in the Company	5856489 Equity Shares (24.87 %)

Bilcare Limited

Bilcare Limited
301 Kamal Kunj
8 Shivaji Housing Society
Pune 411 016 India

Tel +91 20 6600 7559

direct.bil@bilcare.com
www.bilcare-group.com

Bilcare Research

Annexure B

Details under Regulation 30 of the SEBI Listing Regulations, read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No.	Particulars	Details
1.	Name of Director / KMP	Dr. Kavita Bhansali (DIN: 05355200)
2.	Reason for change viz. ~~appointment~~, re-appointment~~,~~ ~~resignation, removal, death or otherwise~~	Reappointment as an Executive Director of the Company.
3.	Date of ~~appointment~~ / re-appointment / ~~cessation~~ (as applicable) & term of appointment / re-appointment	Effective Date: 15 August 2026. Term of Appointment: Appointed for a period of 5 (five) consecutive years with effect from 15 August 2026, subject to the approval of the Members of the Company.
4.	Brief profile (in case of reappointment)	Ms. Kavita Bhansali, daughter of Mr. Mohan H. Bhandari, Promoter of the Company & Sister of Mr. Shreyans Bhandari, Chairman & Managing Director of the Company, holds MBA degree from Indian School of Business, Hyderabad and a Bachelor's degree in Homeopathic Medicine and Surgery from Pune University. She brings knowledge & technology insights for innovation in healthcare, product & services development and marketing to Pharma companies globally with over a decade of experience in the field.
5.	Disclosure of relationships between directors (in case of appointment of a Director)	Dr. Kavita Bhansali Executive Director of the Company and is related to key board members as under: • Daughter of Mr. Mohan Bhandari (Founder, Promoter and Chief Executive Officer) • Sister of Mr. Shreyans Bhandari (Chairman & Managing Director)
6.	Information required pursuant to BSE Circular ref no. LIST/COMP/14/2018-19 and NSE Circular ref no. NSE/CPL/2018/24 dated June 20, 2018	Dr. Kavita Bhansali is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.
7.	Shareholding in the Company	NIL

Bilcare Limited

Bilcare Limited
301 Kamal Kunj
8 Shivaji Housing Society
Pune 411 016 India

Tel +91 20 6600 7559

direct.bil@bilcare.com
www.bilcare-group.com

Bilcare Research

Annexure C

Disclosure under Regulation 30 of the SEBI LODR Regulations – Change in Key Managerial Personnel

Details under Regulation 30 of the SEBI Listing Regulations, read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No.	**Particulars**	**Details**
1.	Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	**Resignation** – On 13 August 2026, Mr. Sagar R. Baheti has tendered his resignation from the post of Company Secretary, Compliance Officer and Key managerial personnel of the Company, due to personal reasons. Mr. Sagar Baheti will be relieved from the services of the Company on close of business hours on 24 September 2026. **Appointment** – The Board of Directors in their meeting held on 13 August 2026, on the basis of recommendations of the Nomination and Remuneration Committee and Audit Committee approved the appointment of Mr. Mayur Dave as the Company Secretary, Compliance Officer and Key managerial personnel of the Company and he will take over the charge on 25 September 2026.
2.	Date of appointment ~~/ re-appointment / cessation (as applicable) &~~ term of appointment ~~/ re-appointment~~	13 August 2026.
3.	Brief profile (in case of appointment)	Mr. Mayur Dave is a Qualified Company Secretary and an Associate Member of the Institute of Company Secretaries of India (ICSI) with over ~11 years of experience in company secretarial functions, statutory compliance and compliance management for listed entities.
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Not applicable

Bilcare Limited

Date: 13 August 2026

To,
The Board of Directors,
Bilcare Limited
Gat No. 1028, At Village Shiroli,
Tal Khed, Rajgurunagar,
Pune - 410505

Subject: Resignation from the position of Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP)

Dear Sir/Madam,

Please accept this letter as formal notification of my resignation from the position of Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) of Bilcare Limited ('Company'). I request that I be relieved from my duties and responsibilities with effect from the close of business hours on September 24, 2026.

I am tendering my resignation in order to pursue other professional opportunities. I hereby confirm that my decision is entirely personal and there are no other material reasons for my resignation.

I request the Board to take note of my resignation and arrange to make the necessary disclosures to the Stock Exchanges in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary Forms and Intimation to Ministry of Corporate Affairs, Stock Exchange and other Statutory /Regulatory Authorities.

I take this opportunity to express my sincere gratitude to the Board of Directors, the management team and all my colleagues for their continuous support, guidance and cooperation during my tenure with the Company.

I wish Bilcare Limited all the best for its future endeavors. Kindly acknowledge the receipt of this letter and arrange to issue my relieving letter in due course.

Thanking you,

Yours faithfully,

Baheti

Sagar R. Baheti
Membership No. A57691

Bilcare Limited
301 Kamal Kunj
8 Shivaji Housing Society
Pune 411 016 India
Tel +91 20 6600 7559
direct.bil@bilcare.com
www.bilcare-group.com

Bilcare Research

Annexure D

Disclosure under Regulation 30 of the SEBI LODR Regulations – Voluntary winding up of Bilcare INC

Details under Regulation 30 of the SEBI Listing Regulations, read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No	Particulars	Details
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	Bilcare INC is a wholly owned subsidiary of the Company in United States of America which has NIL turnover in the last Financial Year i.e. 2025-26.
2.	Date on which the agreement for sale has been entered into	Not Applicable
3.	The expected date of completion of sale/disposal	The Application shall be submitted to the concerned statutory authority and the updates, if any will be communicated.
4.	Consideration received from such sale/disposal	Not Applicable
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Not Applicable
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Not Applicable
7.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to slump sale	Not Applicable

Bilcare Limited